

Birmingham Breast Pathology Update Course

November 6th, 2026 - 9.15am to 5.00pm

Who should attend

- Practising Pathologists
- Pathology Fellows and Trainees
- Biomedical Scientists



Programme

- Expression profiling which test for which patients?
- Updates from UK NEQAS
- Highlights from the WHO Book 6th edition
- Fibroepithelial lesions and updated Phyllodes tumours guidance
- FEA, intraductal proliferations and microinvasion
- Apocrine lesions of the breast
- Invasive carcinomas and neuroendocrine tumours
- Interesting cases from second opinion practice
- Approach to spindle cell lesions of the breast
- AI applications reducing unnecessary biopsies in one stop clinics
- Update on lobular carcinoma, current classification and significance
- MDT Scenarios to learn from
- Slide Seminar, Q&A

Register NOW:

<https://birminghambreastpathology.co.uk/bbpuc-register/>

I would like to invite you to our 2026 annual multi-disciplinary breast course in partnership with University of Birmingham. This year I am especially excited to have **Professor Stuart Schnitt** from Harvard, USA join our faculty. The course will be delivered virtually ONLY for the seventh time!

This is an exciting opportunity to learn from the experts in an interactive and interesting way. The course will provide an update on challenging breast lesions, latest guidelines, educational MDT scenarios, Questions and Answers and slide seminar.

Confirmed speakers: *Professor Stuart Schnitt (Harvard), Professors Sarah Pinder (London), Emad Rakha (Nottingham), Cecily Quinn (Dublin), Abeer Shaaban (Birmingham), Daniel Rea (Birmingham), Dr Clinton Boyd (Belfast), Dr Elena Provenzano (Cambridge) and Mr Naren Basu (Birmingham), Dr Nisha Sharma (Leeds), Miss Raghavan Vidya (Wolverhampton), Dr Bruce Tanchel (Birmingham), Mr Jamie Vathish (Birmingham) plus Dr Soha Elshiekh (UCL London).*

Abeer Shaaban

 **VENTANA**
A Member of the Roche Group

HOLOGIC
The Science of Sure

UNIVERSITY OF
BIRMINGHAM

 INSTITUTE OF
CANCER AND
GENOMIC SCIENCES

**EXACT
SCIENCES**
is now
ABBOTT




AstraZeneca

HistoCyt
laboratories
Quality in Control